{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T05:02:52Z","timestamp":1698037372807},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,7,21]],"date-time":"2006-07-21T00:00:00Z","timestamp":1153440000000},"content-version":"vor","delay-in-days":5346,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1991,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A novel 21\u2010kDa protein (p21) was isolated from auto\u2010immune complexes, found in sera of 14 patients with malignant urogenital tumors and isolated on Protein A\u2010Sepharose. Isolated complexes were analyzed in 15% polyacrylamide\u2010SDS minigels. After staining with Coornassie blue R, the bands were scanned with a clinical densitometer. The level of p21 in sera of cancer patients was 3 times higher than that found in normal individuals. An attempt was made to correlate consecutive levels of p21 in the sera of these cancer patients with the clinical course. In 4 cases a significant decrease (57\u201075%) in the level of p21 was observed in parallel with response to treatment. In 9 of 10 cases where no response or tumor progression was observed, the relative abundance of p21 increased or remained unchanged. Thus, the level of p21 was indicative of progression or regression of the disease in 13 out of 14 patients. Similar high levels of p21 in sera were also found in 22 patients with benign hyperplasia of prostate. The p21 protein was not immunoreactive with known anti\u2010<jats:italic>ras<\/jats:italic> antibodies such as Y13\u2010259, 142\u201024E05 and anti\u2010rap1. Partial amino acid analysis of this protein showed no complete homology to any known protein, but a partial homology to known bacterial proteins involved in DNA replication or transcription was observed. Monitoring of the novel p21 levels before and after treatment may be useful in follow\u2010up of cancer patients, providing evidence of response to treatment.<\/jats:p>","DOI":"10.1002\/ijc.2910490610","type":"journal-article","created":{"date-parts":[[2007,2,19]],"date-time":"2007-02-19T22:46:59Z","timestamp":1171925219000},"page":"861-866","source":"Crossref","is-referenced-by-count":5,"title":["A novel 21\u2010kDa protein as a serum marker for benign and malignant urogenital tumors: Preliminary communication"],"prefix":"10.1002","volume":"49","author":[{"given":"C.","family":"Shalitin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Epelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Valansi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Mekori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Lover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,21]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)44057-2"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198310133091503"},{"key":"e_1_2_1_4_1","unstructured":"Benter T. Grundner\u2010Culmann E. Schmoll H. Poliwoda H. Shalitin C.andNeubauer V. In:Proc. 97th Meeting of the German Association for Internal Medicine Wiesbaden (1991)."},{"key":"e_1_2_1_5_1","doi-asserted-by":"crossref","first-page":"16744","DOI":"10.1016\/S0021-9258(18)37454-4","article-title":"Purification and characterization of the 22,000 dalton GTP\u2010binding protein substrate for ADP\u2010ribosylation by Botulinum toxin, G22K","volume":"263","author":"Bokoch G. M.","year":"1988","journal-title":"J. biol. Chem."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2670407"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.10.3234"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.1860030404"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/jb.169.8.3556-3563.1987"},{"key":"e_1_2_1_10_1","first-page":"488","volume-title":"Methods in enzymology","author":"Harrington M. G.","year":"1990"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60798-8"},{"key":"e_1_2_1_12_1","first-page":"115","article-title":"Ras p21 onco\u2010protein in the sera of mice carrying an experimentally induced tumor and in human cancer patients","volume":"4","author":"Kakkamas A.","year":"1990","journal-title":"In\u2010Vivo"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)37376-9"},{"key":"e_1_2_1_14_1","first-page":"1048","article-title":"Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas","volume":"44","author":"Klug L. T.","year":"1984","journal-title":"Cancer Res."},{"key":"e_1_2_1_15_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/clinchem\/30.5.649","article-title":"Measurement of prostate\u2010specific antigen by radioimmunoassay","volume":"30","author":"Liedke R. J.","year":"1984","journal-title":"Clin. Chem."},{"key":"e_1_2_1_16_1","first-page":"602","volume-title":"Methods in enzymology","author":"Matsudaira P.","year":"1990"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0147-619X(88)90039-X"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(89)81339-0"},{"key":"e_1_2_1_19_1","first-page":"74","article-title":"Detection of a 21kDa protein in sera of patients with urogenital tumors","volume":"3","author":"Shalitin C.","year":"1990","journal-title":"Cancer J."},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)41174-8"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)41175-X"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60024-X"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(89)80017-8"},{"key":"e_1_2_1_24_1","first-page":"159","article-title":"Purification of a human prostate specific antigen","volume":"17","author":"Wang M. C.","year":"1979","journal-title":"Invest. Urol."},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/jb.170.8.3375-3383.1988"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910490610","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910490610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T02:38:59Z","timestamp":1698028739000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910490610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1991,12]]}},"alternative-id":["10.1002\/ijc.2910490610"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910490610","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,12]]}}}